A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint
Authors
Keywords
-
Journal
Clinical Epigenetics
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-02-03
DOI
10.1186/s13148-021-01014-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-mesothelin (CRS-207) With or Without Nivolumab in Patients with Pancreatic Cancer
- (2020) Takahiro Tsujikawa et al. CLINICAL CANCER RESEARCH
- Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer
- (2020) Victoria M. Kim et al. JCI Insight
- The emerging role of epigenetic therapeutics in immuno-oncology
- (2019) Michael J. Topper et al. Nature Reviews Clinical Oncology
- A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer
- (2019) Mark Yarchoan et al. Cancer Medicine
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
- (2018) Franck Pagès et al. LANCET
- Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages
- (2018) Amber E. de Groot et al. Oncotarget
- Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs
- (2018) Brian J. Christmas et al. Cancer Immunology Research
- Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study
- (2017) Nilofer S. Azad et al. Oncotarget
- HDAC inhibition potentiates immunotherapy in triple negative breast cancer
- (2017) Manuela Terranova-Barberio et al. Oncotarget
- Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis
- (2017) Takahiro Tsujikawa et al. Cell Reports
- Combining Epigenetic and Immunotherapy to Combat Cancer
- (2016) Katherine B. Chiappinelli et al. CANCER RESEARCH
- Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study
- (2016) Roisin M. Connolly et al. CLINICAL CANCER RESEARCH
- Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
- (2016) Bernhard Mlecnik et al. IMMUNITY
- Inducible expression of cancer-testis antigens in human prostate cancer
- (2016) Erika Heninger et al. Oncotarget
- Epigenetic modifiers reduce inflammation and modulate macrophage phenotype during endotoxemia-induced acute lung injury
- (2015) J. Thangavel et al. JOURNAL OF CELL SCIENCE
- Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting
- (2015) Evan J Lipson et al. Journal of Translational Medicine
- Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
- (2015) Jean-Pierre J Issa et al. LANCET ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epigenetic therapy for solid tumors: from bench science to clinical trials
- (2015) Yen-Yi Juo et al. Epigenomics
- Image Analyzer-Based Assessment of Tumor-Infiltrating T Cell Subsets and Their Prognostic Values in Colorectal Carcinomas
- (2015) Younghoon Kim et al. PLoS One
- Alterations of immune response of non-small cell lung cancer with Azacytidine
- (2015) John Wrangle et al. Oncotarget
- Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
- (2015) Huili Li et al. Oncotarget
- A Safety and Feasibility Study of an Allogeneic Colon Cancer Cell Vaccine Administered with a Granulocyte–Macrophage Colony Stimulating Factor–Producing Bystander Cell Line in Patients with Metastatic Colorectal Cancer
- (2014) Lei Zheng et al. ANNALS OF SURGICAL ONCOLOGY
- Inhibiting DNA Methylation by 5-Aza-2′-deoxycytidine Ameliorates Atherosclerosis Through Suppressing Macrophage Inflammation
- (2014) Qiang Cao et al. ENDOCRINOLOGY
- The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity
- (2013) David M. Woods et al. MELANOMA RESEARCH
- Epigenetic Reprogramming in Cancer
- (2013) M. L. Suva et al. SCIENCE
- Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide
- (2012) Sandra Coral et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review
- (2010) Katsuhiko Nosho et al. JOURNAL OF PATHOLOGY
- Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
- (2008) D. Laheru et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
- (2008) Johan Vansteenkiste et al. INVESTIGATIONAL NEW DRUGS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started